Recent ARVN News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2026 09:34:23 PM
- Arvinas Employees Give Back During Company-wide Impact Day • GlobeNewswire Inc. • 05/18/2026 02:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 08:17:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 08:16:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 08:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 11:15:37 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 11:14:36 AM
- Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/12/2026 11:05:00 AM
- Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant) • GlobeNewswire Inc. • 05/12/2026 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/11/2026 09:18:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/08/2026 10:06:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/08/2026 10:05:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/08/2026 10:05:24 PM
- Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026 • GlobeNewswire Inc. • 05/05/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/01/2026 04:58:05 PM
- Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer • GlobeNewswire Inc. • 05/01/2026 04:43:18 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/29/2026 01:46:20 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/29/2026 01:24:28 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/29/2026 01:23:43 PM
- Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days • GlobeNewswire Inc. • 03/18/2026 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2026 11:25:22 PM
- Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders • GlobeNewswire Inc. • 03/11/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 02:01:10 AM
